1. Strohmaier W. Epidemiologie und Pathogenese der Urolithiasis. Die Urologie. Part of the series Springer Reference Medizin. 2016: 473 – 478.
2. Бакетин П.С., Моллаев Р.А., Д.А. Мазуренко, Григорьев В.Е. и соавт. Патогенетические варианты мочекаменной болезни. Педиатр. 2017; N 8 (1): 89 – 99.
3. Coe F.L., Evan A.P., Worcester E.M., Lingeman J.E. Three pathways for human kidney stone formation. Urol Res. 2010; N 38 (3): 147 – 60. doi: 10.1007/s00240-010-0271-8.
4. Evan A.P., Lingeman J., Coe F., Shao Y., Miller N., et al. Renal histopathology of stone- forming patients with distal renal tubular acidosis. Kidney Int. 2007; N 71 (8): 795 – 801.
5. Kok D.J., Khan S.R. Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int. 1994; N 46 (3): 847 – 54.
6. Белай С.И., Довбыш М.А., Белай И.М. Мочекаменная болезнь: актуальность вопроса и перспективы его развития. Вестник ВГМУ. Украина. 2016; N 15 (5): 19 – 26.
7. Борисов В.В. Мочекаменная болезнь. Терапия больных камнями почек и мочеточников. М., 2011. с. 96.
8. Trinchieri A., Curhan G., Karlsen S., Jun Wu К. Epidemiology. Stone Disease. Paris: Health Publications, 2003; с. 13 – 30.
9. Stamatelou K.K., Francis M.E., Jones C.A., Nyberg L.M., Curhan G.C. Time trends in reported prevalence of kidney stones in the United States: 1976 – 1994. Kidney Int. 2003; N 63 (5): 1817 – 23.
10. Trinchieri A., Ostini F., Nespoli R., Rovera F., Montanari E., et al. A prospective study of recurrence rate and risk factors for recurrence after a first renal stone. J Urol. 1999; N 162 (1): 27 – 30. doi: 10.1097/00005392-199907000-00007.
11. Rule A.D., Lieske J.C., Li X., Melton L.J.3rd., Krambeck A.E., et al. The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol. 2014; N 25 (12): 2878 – 86. doi: 10.1681/ASN.2013091011.
12. Гаджиев Н.К., Бровкин С.С., Григорьев В.Е., Дмитриев В.В., Малхасян В.А., и др. Метафилактика мочекаменной болезни: новый взгляд, современный подход, мобильная реализация. Урология. 2017; 1: 124 – 129.
13. Hesse A., Brändle E.., Wilbert D., Köhrmann K.U., Alken P. Study on the prevalence and incidence of urolithiasis in Germany comparing the years 1979 vs. 2000. Eur Urol. 2003; N 44 (6): 709 – 13.
14. Leusmann D.B. Whewellite, weddellite and company: where do all the strange names originate? BJU Int. 2000; N 86 (4): 411 – 3.
15. Leusmann D.B., Blaschke R., Schmandt W. Results of 5,035 stone analyses: a contribution to epidemiology of urinary stone disease. Scand J Urol Nephrol. 1990; N 24 (3): 205 – 10.
16. Kim S.C., Burns E.K., Lingeman J.E., Paterson R.F., McAteer J.A., et al. Cystine calculi: correlation of CT-visible structure, CT number, and stone morphology with fragmentation by shock wave lithotripsy. Urol Res. 2007; N 35 (6): 319 – 24.
17. Perlmutter A.E., Talug C., Tarry W.F., Zaslau S., Mohseni H., et al. Impact of stone location on success rates of endoscopic lithotripsy for nephrolithiasis. Urology. 2008; N 71 (2): 214– 7. doi: 10.1016/j.urology.2007.09.023.
18. Eisner B.H., Reese A., Sheth S., Stoller M.L. Ureteral stone location at emergency room presentation with colic. J Urol. 2009; N 182 (1): 165 – 8. doi: 10.1016/j.juro.2009.02.131.
19. Segura J.W., Preminger G.M., Assimos D.G., Dretler S.P., Kahn R.I., et al. Ureteral Stones Clinical Guidelines Panel summary report on the management of ureteral calculi. The American Urological Association. J Urol. 1997; N 158 (5): 1915 – 21.
20. Chung B.I., Aron M., Hegarty N.J., Desai M.M. Ureteroscopic versus percutaneous treatment for medium-size (1 – 2-cm) renal calculi. J Endourol. 2008; N 22 (2): 343 – 6. doi: 10.1089/end.2006.9865.
21. Keoghane S., Walmsley B. Hodgson D. The natural history of untreated renal tract calculi. BJU Int. 2010; N 105 (12): 1627 – 9. doi: 10.1111/j.1464-410X.2010.09389.x.
22. Straub M., Strohmaier W.L., Berg W., Beck B., Hoppe B., et al. Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on Stone Disease for the upcoming German Urolithiasis Guideline. World J Urol. 2005; N 23 (5): с. 309 – 23.
23. Hesse A., Tiselius B.H., Siener S.R., et al. Urinary Stones, Diagnosis, Treatment and Prevention of Recurrence. 3rd edition. 2009, Basel.
24. Basiri A., Shakhssalim N. Khoshdel A.R., Javaherforooshzadeh A., Basiri H., et al. Familial relations and recurrence pattern in nephrolithiasis: new words about old subjects. Urol J. 2010 N 7 (2): 81 – 6.
25. Goldfarb D.S., Fischer M.E., Keich Y., Goldberg J. A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. Kidney Int. 2005; N 67 (3): 1053 – 61.
26. Asplin J.R., Coe F.L. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol. 2007; N 177 (2): 565 – 9.
27. Gonzalez R.D., Canales B.K. Kidney stone risk following modern bariatric surgery. Curr Urol Rep. 2014; N 15 (5): 401. doi: 10.1007/s11934-014-0401-x.
28. Rendina D., De Filippo G., D'Elia L., Strazzullo P. Metabolic syndrome and nephrolithiasis: a systematic review and meta-analysis of the scientific evidence. J Nephrol. 2014; N 27 (4): 371 – 6. doi: 10.1007/s40620-014-0085-9.
29. Dell'Orto V.G., Belotti E.A., Goeggel-Simonetti B., Simonetti G.D., Ramelli G.P., et al. Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review. Br J Clin Pharmacol. 2014; N 77 (6): 958 – 64. doi: 10.1111/bcp.12283.
30. Mufti U.B., Nalagatla S.K. Nephrolithiasis in autosomal dominant polycystic kidney disease. J Endourol. 2010; N 24 (10): 1557 – 61. doi: 10.1089/end.2010.0093.
31. Chen Y., DeVivo M.J., Roseman J.M. Current trend and risk factors for kidney stones in persons with spinal cord injury: a longitudinal study. Spinal Cord. 2000; N 38 (6): 346 – 53.